Synchronous Duodenal Carcinoid and Adenocarcinoma of the Colon

Limin Gao, Seth Lipka, Jorge Hurtado-Cordovi, Boris Avezbakiyev, Alejandro Zuretti, Kaleem Rizvon, Paul Mustacchia

Abstract

Carcinoid tumors are a histological subtype of well differentiated, low to intermediate grade, slow-growing neuroendocrine malignancies capable of secreting bioactive peptides, such as 5-hydroxytryptamine (5-HT, serotonin), chromogranin-A and chromogranin-C. Here we present a case of a duodenal carcinoid that simultaneously occurred with adenocarcinoma of the colon. A 59-year-old male with a past medical history of hepatitis C and hypertension presented complaining of worsening abdominal pain associated with 2 - 3 episodes per week of bright red blood per rectum for the past month. He also reported a 20 pounds weight loss in the last 6 months. Social history was significant for a 15 pack year history. Vitals on admission were within normal limits. Physical exam was significant for right upper quadrant tenderness without guarding, rebound, or organomegaly. Rectal exam revealed no blood or masses. Laboratory results showed iron deficiency anemia with hemoglobin of 9.6 K/mm$^3$. Esophagogastroduodenoscopy revealed a 4 mm duodenal polyp. Colonoscopy was terminated early secondary to a large circumferential obstructing mass found in the descending colon. Immunohistochemistry of the duodenal biopsy was positive for synaptophysin and chromogranin-A; consistent with the diagnosis of stage I carcinoid tumor. Biopsy results of the colonic mass showed a stage I well-differentiated adenocarcinoma. The patient underwent a left colectomy and partial duodenectomy; he remains in remission after 2 year of close follow up. When the diagnosis of small bowel carcinoid is made, further screening for other primary neoplasms should be sought to prevent potential late stage diagnosis of synchronous malignancies. This is crucial because patients' demise usually result from the associate tumor and not the carcinoid component. Finally, we would like to raise clinician’s awareness regarding the incidence of this entity since some of the studies suggest that it is more common than it was previously thought.

Keywords: Synchronous tumor; Duodenal carcinoid

Introduction

Carcinoid tumors are relatively slow-growing neuroendocrine tumors that are capable of secreting bioactive peptides, such as 5-hydroxytryptamine (5-HT, serotonin), chromogranin-A and chromogranin-C. The most common site for carcinoid tumor origin is the gastrointestinal tract (73-85%) with the majority of patients being asymptomatic [1]. While the occurrence of duodenal carcinoid is only 1.5-5%, its association with synchronous colon adenocarcinoma is rare. We described a case of a duodenal carcinoid that simultaneously occurred with adenocarcinoma of the colon [1-2].

Case Report

A 59-year-old male with a past medical history of hepatitis C and hypertension presented complaining of worsening abdominal pain associated with bright red blood per rectum for the past month. The pain was 7/10 in intensity, constant, non-radiating, with no alleviating or aggravating factors. He admits having 2 - 3 episodes of bloody stools per week. He also reported a 20 pounds weight loss in the last 6 months. Review of systems was otherwise negative. Social history was significant for a 15 pack year history. He denied family history gastrointestinal malignancies. Vitals on admission...
were within normal limits. Physical exam was significant for right upper quadrant tenderness without guarding, rebound, or organomegaly. Rectal exam revealed no blood or masses. Laboratory results showed iron deficiency anemia with hemoglobin of 9.6 K/mm$^3$. Liver related tests and coagulation profile were within normal limits. Esophagogastroduodenoscopy revealed a 4mm duodenal polyp (Fig. 1). Colonoscopy was terminated early secondary to a large circumferential obstructing mass (Fig. 2) found in the descending colon. Immunohistochemistry of the duodenal biopsy was positive for synaptophysin and chromogranin-A (Fig. 3); consistent with the diagnosis of stage I carcinoid tumor. Biopsy results of the colonic mass showed a stage I well-differentiated adenocarcinoma (Fig. 4). The patient underwent a left colectomy and partial duodenectomy. He remains in remission after 2 year of close follow up.

**Discussion**

In the gastrointestinal tract, carcinoid tumors are found most often in the jejunum (13.4-17.6%), rectum (10-18.5%), colon (7.6-9.5%) and appendix (2.4-7.6%); with duodenal carcinoids accounting for less than 2% of all carcinoids [2, 3]. The annual incidence of duodenal carcinoids is 0.07/100,000 [4]. Carcinoid tumors can present with a variety of clinical symptoms and are difficult to diagnose. However, most carcinoids have an asymptomatic, indolent course with late metastases. Furthermore, 80% of cases present with the classic carcinoid syndrome symptoms, likely because up 91% are found to have distant metastases at the time of diagnosis. The liver is the most common site of metastasis. These symptoms are due to increased production of 5-hydroxytryptamine (5-HT), and include flushing, diarrhea, palpitations, spasmic abdominal pain and bronchial constriction. Diagnosis depends on histopathological examination and positive reactions to neuroendocrine markers such as synaptophysin, neuron-spe-
sific enolase, and glycoprotein chromogranin A. The rapid
technological advancements such as endoscopic procedures,
ultrasound (US), computed tomography (CT), magnetic reso-
nance imaging (MRI), positron emission tomography (PET),
and radio labeled somatostatin receptor scintigraphy (SRS,
OctreoScan), have enhanced significantly the diagnosis of
carcinoid tumors allowing for a more accurate delineation
of metastases. The five year survival dependent on the stage
and location of the tumor; with only a 25% survival for pa-
ients with metastasis, compared to an 88% for those with
local disease [5, 6].

Multiple factors must be taken into consideration when
planning therapy. Well-differentiated, nonfunctional duo-
denal carcinoids that are limited to the mucosa/submucosa
and are no more than 10 mm in size can be endoscopically
removed. In these cases the preferred procedure to achieve
complete excision of the tumor is endoscopic mucosal resec-
tion (EMR). Larger masses (10 - 20 mm) with similar char-
acteristics as above can be removed by endoscopy or surgery.
Surgical management is the treatment of choice for duodenal
carcinoids that are nonfunctional but more than 20 mm in
size. Tumors extending beyond the submucosa (T2-T4) or
that have metastasized to lymph nodes should be managed
surgically [7-9].

The incidence of synchronous tumors of the colon rages
from 2 to 11 percent [10]. While adenocarcinomas are the
most common colorectal malignancy, the incidence of
carcinoid malignant tumors is 1-4/1,000,000 per year [11].
According to the SEER (Surveillance, Epidemiology, and
End Results Program, National Cancer Institute, USA), 29% of
patients with gastrointestinal carcinoid had an additional
malignancy. Gerstle et al studied 69 patients with gastroin-
testinal tract carcinoids and found that 29 of them (42%)
had a synchronous tumor, with colorectal adenocarcinoma
being the most common associate malignancy. Berge and
Linell reported that out of 199 patients with carcinoid tumor
81 (40.7%) had one or more coexisting synchronous ma-
lignancy with up to 35.8% of the accompanying neoplasm
occurring in the gastrointestinal tract. Most of the patients
with synchronous malignancies had no symptoms relating
to the carcinoid tumor. Asymptomatic duodenal carcinoids
are usually small and confined to the submucosa; therefore, it
is possible to perform a segmental intestinal resection as it
was done in our case. Whenever a synchronous tumor with
a non-metastatic carcinoid component is encounter, its prog-
nosis is determined by the associate malignancy, and the vast
majority of patients succumb to the non-carcinoid constitu-
ent [12-16].

In conclusion, when the diagnosis of small bowel carci-
noid is made, further screening for other primary neoplasms
should be sought to prevent potential late stage diagnosis of
synchronous malignancies. This is crucial because patients’
demise usually result from the associate tumor and not the
carcinoid component. Finally, we would like to raise clini-
cian’s awareness regarding the incidence of this entity since
some of the studies suggest that it is more common than it
was previously thought.

Conflict of Interest

All cited authors have read this case report and have directly
contributed to its development. This manuscript has never
been published, and is not under consideration for publish-
ing in any other journal. Pictures can be published in black
and white. This article did not receive any funding from any
institution.

References

1. Babovic-Vuksanovic D, Constantiou CL, Rubin J, Rowland CM, Schaia DJ, Karnes PS. Familial occur-
rence of carcinoid tumors and association with other ma-
lignant neoplasms. Cancer Epidemiol Biomarkers Prev.
1999;8(8):715-719.
2. Modlin IM, Sandor A. An analysis of 8305 cases of car-
cinoid tumors. Cancer. 1997;79(4):813-829.
3. Soga J. Early-stage carcinoids of the gastrointesti-
nal tract: an analysis of 1914 reported cases. Cancer.
2005;103(8):1587-1595.
4. Oberg K: Gastrointestinal carcinoid tumors (gastro-
intestinal neuroendocrine tumors) and the carcinoid
syndrome; in Feldman M, Friedman L, Brandt L (eds):
Sleisenger and Fordtran’s Gastrointestinal and Liver
Disease, ed 9. Philadelphia, Elsevier/Saunders, 2010,
475-490.
5. Soga J, Yakuwa Y, Osaka M. Carcinoid syndrome: a
statistical evaluation of 748 reported cases. J Exp Clin
Cancer Res. 1999;18(2):133-141.
6. McDermott EW, Guduric B, Brennan MF. Prognostic
variables in patients with gastrointestinal carcinoid tu-
mours. Br J Surg. 1994;81(7):1007-1009.
7. Hoffmann KM, Furukawa M, Jensen RT. Duodenal
neuroendocrine tumors: Classification, functional syn-
dromes, diagnosis and medical treatment. Best Pract Res
Clin Gastroenterol. 2005;19(5):675-697.
8. Shimizu N, Kaminishi M. [Management of patients
with neuroendocrine tumors of the esophagus, stom-
ach, and duodenum]. Nihon Geka Gakkai Zasshi.
2008;109(3):147-151.
9. Scherubl H, Schwertner C, Steinberg J, Stolzel U, Pohl
J, Dralle H, Kloppel G. [Neuroendocrine tumors of the
small bowels are on the rise: early tumors and their man-
agement]. Z Gastroenterol. 2010;48(3):406-413.
10. Slater G, Aufses AH, Jr., Szporn A. Synchronous car-
cinoma of the colon and rectum. Surg Gynecol Obstet.
1990;171(4):283-287.
11. Hiripi E, Bermejo JL, Sundquist J, Hemminki K. Familial gastrointestinal carcinoid tumours and associated cancers. Ann Oncol. 2009;20(5):950-954.
12. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934-959.
13. Gerstle JT, Kauffman GL, Jr., Koltun WA. The incidence, management, and outcome of patients with gastrointestinal carcinoids and second primary malignancies. J Am Coll Surg. 1995;180(4):427-432.
14. Berge T, Linell F. Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand A. 1976;84(4):322-330.
15. Srilatha PS. Concurrence of duodenal carcinoid and diffuse gastric adenocarcinoma: a rare phenomenon. Saudi J Gastroenterol. 2007;13(4):197-199.
16. McCabe HL. Adenocarcinoma of the gastro-oesophageal junction with a synchronous carcinoid of the duodenum. Postgrad Med J. 2001;77(906):255-256.